- Home
- GILT vs SLS Comparison
GILT vs SLS Comparison
Compare GILT & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GILT | SLS |
|---|---|---|
| Founded | 1987 | 2012 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 877.0M | 924.5M |
| IPO Year | 1997 | 2007 |
Fundamental Metrics
Financial Performance| Metric | GILT | SLS |
|---|---|---|
| Price | $10.02 | $13.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $19.00 | $10.00 |
| AVG Volume (30 Days) | 580.1K | ★ 6.7M |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.06 | N/A |
| Revenue Next Year | $11.72 | $110.98 |
| P/E Ratio | $42.82 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.50 | $1.39 |
| 52 Week High | $20.99 | $15.88 |
Technical Indicators
Market Signals| Indicator | GILT | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 38.79 | 52.52 |
| Support Level | N/A | $11.43 |
| Resistance Level | $12.24 | $15.77 |
| Average True Range (ATR) | 0.35 | 1.16 |
| MACD | -0.02 | -0.08 |
| Stochastic Oscillator | 19.78 | 33.49 |
Price Performance
Historical ComparisonAbout GILT Gilat Satellite Networks Ltd.
Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company operates in three operating segments: Gilat Commercial Division, Gilat Defense Division, and Gilat Peru Division. The majority of its revenue is generated from the Gilat Commercial segment.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.